Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study of CDX-0159 in Patients With Prurigo Nodularis

ClinicalTrials.gov ID: NCT04944862

Public ClinicalTrials.gov record NCT04944862. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to explore the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 (barzolvolimab) in patients with Prurigo Nodularis.

Study identification

NCT ID
NCT04944862
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Celldex Therapeutics
Industry
Enrollment
24 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 8, 2021 (Actual)
Primary completion
Jul 31, 2023 (Actual)
Completion
Jul 31, 2023 (Actual)
Last update posted
Aug 14, 2023

2021 – 2023

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Desert Sky Dermatology Tempe Arizona 85284 —
University of Miami, Dermatology Clinical Trials Unit Miami Florida 33125 —
Revival Research Institute, LLC Troy Michigan 48084 —
University of New Mexico Albuquerque New Mexico 87131 —
Markowitz Medical/Optiskin New York New York 10128 —
Central Sooner Research Norman Oklahoma 73071 —
Center for Clinical Studies, LTD.LLP Houston Texas 77004 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04944862, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 14, 2023 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04944862 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →